肥胖型星形细胞瘤II级的预后相关性:肥胖型成分及MR影像特征与非肥胖型II级星形细胞瘤的比较
回顾性纳入78例II级星形细胞瘤患者(肥胖型29例、非肥胖型49例),随访超过5年,比较其MR影像特征与进展时间。肥胖型患者出现弥散受限、胆碱/肌酸及胆碱/NAA比值升高等高级别特征更频繁,中位进展时间显著更短(53.1 vs 68个月,P < .001)。肥胖型组织病理学与低ADC值是进展时间缩短的独立相关因素。
要点
- 肥胖型II级星形细胞瘤初诊时可出现类似高级别胶质瘤的MR表现,包括弥散受限和MRS代谢物比值升高。
- 肥胖型患者中位进展时间较非肥胖型显著缩短(53.1 vs 68个月,P < .001)。
- 肥胖型组织病理学(HR=3.42,P=.015)与低ADC值(HR=3.61,P=.001)为进展时间缩短的独立相关因素。
核心结论
- 肥胖型II级星形细胞瘤初诊时MR表现可类似高级别胶质瘤,且较非肥胖型更早转化为高级别;DWI低ADC值可能有助于对II级星形细胞瘤患者进行进展风险分层。
研究设计与样本
- 回顾性研究,纳入10年期间78例随访超过5年的II级星形细胞瘤患者,其中病理证实的肥胖型29例、非肥胖型49例;分析增强T1加权、DWI、DSC、MRS及临床资料,采用Cox比例风险模型进行进展时间的多因素分析。
关键影像表现/征象
- 肥胖型较非肥胖型更频繁出现弥散受限(P < .001)。
- 肥胖型较非肥胖型更频繁出现胆碱/肌酸比值升高(P = .02)。
- 肥胖型较非肥胖型更频繁出现胆碱/NAA比值升高(P = .015)。
诊断标准与关键数值
- 肥胖型患者中位进展时间53.1个月 vs 非肥胖型68个月,肥胖型显著缩短(P < .001)。
- 肥胖型组织病理学与进展时间缩短独立相关(HR=3.42,P=.015)。
- 低ADC值与进展时间缩短独立相关(HR=3.61,P=.001)。
临床应用与阅片要点
- 对II级星形细胞瘤,阅片时需关注DWI弥散受限及MRS胆碱/肌酸、胆碱/NAA比值升高,这些表现可与高级别胶质瘤相似。
- DWI低ADC值可能有助于对II级星形细胞瘤患者进行进展风险分层。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: To determine if gemistocytic grade II astrocytoma (GemA) and its MR imaging characteristics are associated with a shorter time-to-progression (TTP) compared with non-gemistocytic grade II astrocytoma (non-GemA).
MATERIALS AND METHODS: We enrolled 78 patients who were followed up more than 5 years (29 pathologically proven GemA and 49 non-GemA) during a 10-year period. Contrast-enhanced T1-weighted, diffusion-weighted imaging (DWI), dynamic susceptibility contrast (DSC), and MR spectroscopy (MRS) and clinical data were retrospectively reviewed. Clinical and MR imaging features were analyzed as possible prognostic factors of high-grade transformation, and multivariate analysis of TTP was performed using Cox proportional modeling.
RESULTS: GemA showed more frequent high-grade features than non-GemA, including diffusion restriction (P < .001), increased choline/creatine (P = .02), and increased choline/NAA ratio (P = .015). Patients with GemA had a significantly shorter median TTP (53.1 vs 68 months; P < .001). A gemistocytic histopathology (hazard ratio = 3.42; P = .015) and low ADC (hazard ratio = 3.61; P = .001) were independently associated with a shorter TTP.
CONCLUSIONS: GemA can present with MR imaging findings mimicking high-grade glioma at initial diagnosis and transforms to high-grade disease earlier than non-GemA. Low ADC on DWI might be useful in stratifying the risk of progression in patients with grade II astrocytoma.
KEY POINTS: • Gemistocytic grade II astrocytoma (GemA) showed more frequent high-grade features than non-GemA. • Patients with GemA had a significantly shorter median TTP than non-GemA. • Gemistocytic histopathology and low ADC were independently associated with shorter TTP.
引用
- Heo YJ, Park JE, Kim HS, et al. Prognostic relevance of gemistocytic grade II astrocytoma: gemistocytic component and MR imaging features compared to non-gemistocytic grade II astrocytoma. Eur Radiol. 2016. PMID: 27858213. doi:10.1007/s00330-016-4649-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。